integrin-modulating therapy prevents fibrosis autoimmunity mouse models scleroderma 
systemic sclerosis ssc common aetiologically mysterious form scleroderma defined pathological fibrosis skin previously healthy adults acquire fibrosis skin viscera association autoantibodies familial recurrence extremely rare causal genes identified although onset fibrosis ssc typically correlates production autoantibodies whether contribute disease pathogenesis simply serve marker disease remains controversial mechanism induction largely unknown study ssc hindered lack animal models recapitulate aetiology complex disease gain foothold pathogenesis pathological skin fibrosis studied stiff skin syndrome sss rare tractable mendelian disorder leading childhood onset diffuse skin fibrosis autosomal dominant inheritance complete penetrance showed previously sss caused heterozygous missense mutations gene fbn1 encoding fibrillin- main constituent extracellular microfibrils sss mutations localize domain fibrillin harbours arg-gly-asp rgd motif needed mediate cell-matrix interactions binding cell-surface integrins show mouse lines harbouring analogous amino acid substitutions fibrillin recapitulate aggressive skin fibrosis prevented integrin-modulating therapies reversed antagonism pro-fibrotic cytokine transforming growth factor beta tgf-beta mutant mice show skin infiltration pro-inflammatory immune cells including plasmacytoid dendritic cells t helper cells plasma cells also autoantibody production findings normalized integrin-modulating therapies tgf-beta antagonism results show alterations cell-matrix interactions sufficient initiate sustain inflammatory pro-fibrotic programmes highlight new therapeutic strategies 
